BRTX - Company ID 0001505497
The table below shows BioRestorative Therapies, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $359.70K | $401.00K | $145.80K | $119.80K | $46.00K | $77.00K |
| Cost of revenue | $23.84K | $28.07K | - | - | - | - |
| Gross profit | $335.86K | $372.93K | $145.80K | - | - | - |
| R&D | $10.09M | $6.71M | $4.03M | $3.51M | $729.06K | $876.83K |
BioRestorative Therapies, Inc. reported annual revenue of $359.70K for fiscal year 2025. That is down 10.3% from $401.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $36.35K (FY 2016) to $359.70K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $5.89M |
| $5.22M |
| $11.33M |
| $15.58M |
| $25.62M |
| $1.79M |
| Operating income | -$15.65M | -$11.56M | -$15.22M | -$18.97M | -$26.31M | -$2.75M |
| Income tax | - | - | - | - | - | - |
| Net income | -$14.24M | -$8.98M | -$10.42M | -$13.22M | -$44.30M | -$11.27M |
| EPS (diluted) | -$1.58 | -$1.16 | -$2.47 | -$3.65 | - | - |